Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

692.80 +9.36 (+1.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 558,692
Open 685.72
Bid (Size) 680.00 (1)
Ask (Size) 693.00 (2)
Prev. Close 683.44
Today's Range 680.00 - 693.81
52wk Range 497.22 - 747.42
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
United Airlines Leads Five Stocks Breaking Resistance As Market Rebounds
United Airlines headlines five stocks to watch for the week ahead. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
 
Via Benzinga

Performance

YTD
+10.48%
+10.48%
1 Month
+2.55%
+2.55%
3 Month
+12.04%
+12.04%
6 Month
+5.87%
+5.87%
1 Year
+37.89%
+37.89%

More News

Read More
Regeneron's Evkeeza Reduces Bad Cholesterol By 48% In Children Aged 5-11 Years
Via Benzinga
How Regeneron Pharmaceuticals Beat Quarterly Projections Without Leaning On Covid
Via Investor's Business Daily
Here's Why This Analyst Cut Price Target On Regeneron
Via Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Via Benzinga
FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule
Via Benzinga
How Heart Drugs Could Pump $10 Billion Into Merck's Coffers
Via Investor's Business Daily
Gilead Stock Earns Rating Upgrade After Quick Turnaround
Via Investor's Business Daily
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Regeneron Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Via Talk Markets
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now
Via Investor's Business Daily
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
Via Investor's Business Daily
Stock Market Jumps, Then Dives After Fed Rate Hikes As Treasury Yields Soar: Weekly Review
Via Investor's Business Daily
$1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
Regeneron Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Earnings Preview: Regeneron Pharmaceuticals
Via Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Via Benzinga
Looking Into Regeneron Pharmaceuticals Inc's Recent Short Interest
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Via Benzinga
If You Invested $100 In Regeneron Pharmaceuticals 10 Years Ago, Here's How Much You Would Have Today
Via Benzinga
54 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.